Does the media prefer CRSP or BEAM?

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 7 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.75 beat Beam Therapeutics' score of 0.23 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DNLI or BEAM?

In the previous week, Beam Therapeutics had 4 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Beam Therapeutics' score of 0.23 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BEAM or EDIT?

In the previous week, Beam Therapeutics had 4 more articles in the media than Editas Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.23 beat Editas Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRME or BEAM?

In the previous week, Beam Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 6 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat Beam Therapeutics' score of 0.23 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Beam Therapeutics (BEAM) Competitors

$24.47 +0.08 (+0.34%)

Closing price 03:59 PM Eastern

Extended Trading

$24.50 +0.03 (+0.11%)

As of 04:10 PM Eastern

Compare

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

Should you buy Beam Therapeutics stock or one of its competitors? Beam Therapeutics's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Prime Medicine (PRME). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Beam Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,499.25	-$581.60M	-$4.76	N/A
Beam Therapeutics	$139.74M	18.06	-$79.99M	-$0.86	N/A

In the previous week, CRISPR Therapeutics and CRISPR Therapeutics both had 7 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.75 beat Beam Therapeutics' score of 0.23 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, suggesting that its share price is 120% more volatile than the broader market.

Beam Therapeutics has a net margin of -54.75% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

CRISPR Therapeutics presently has a consensus target price of $67.94, suggesting a potential upside of 24.83%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 100.57%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Beam Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.78	-$512.54M	-$2.84	N/A
Beam Therapeutics	$139.74M	18.06	-$79.99M	-$0.86	N/A

In the previous week, Beam Therapeutics had 4 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Beam Therapeutics' score of 0.23 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics presently has a consensus price target of $35.85, suggesting a potential upside of 77.24%. Beam Therapeutics has a consensus price target of $49.00, suggesting a potential upside of 100.57%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Denali Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, meaning that its stock price is 120% more volatile than the broader market.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Beam Therapeutics beats Denali Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Beam Therapeutics compare to Editas Medicine?

Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Beam Therapeutics has a beta of 2.2, suggesting that its share price is 120% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

In the previous week, Beam Therapeutics had 4 more articles in the media than Editas Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.23 beat Editas Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Beam Therapeutics has a net margin of -54.75% compared to Editas Medicine's net margin of -157.32%. Beam Therapeutics' return on equity of -30.71% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Editas Medicine	-157.32%	-196.63%	-38.17%

Beam Therapeutics currently has a consensus price target of $49.00, indicating a potential upside of 100.57%. Editas Medicine has a consensus price target of $5.80, indicating a potential upside of 129.70%. Given Editas Medicine's higher possible upside, analysts plainly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	18.06	-$79.99M	-$0.86	N/A
Editas Medicine	$40.52M	9.57	-$160.06M	-$0.75	N/A

Summary

Beam Therapeutics beats Editas Medicine on 14 of the 17 factors compared between the two stocks.

How does Beam Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.33	-$412.69M	-$3.36	N/A
Beam Therapeutics	$139.74M	18.06	-$79.99M	-$0.86	N/A

In the previous week, Beam Therapeutics had 7 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 0 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.84 beat Beam Therapeutics' score of 0.23 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Intellia Therapeutics	Very Positive
Beam Therapeutics	Neutral

Intellia Therapeutics presently has a consensus target price of $20.98, indicating a potential upside of 71.52%. Beam Therapeutics has a consensus target price of $49.00, indicating a potential upside of 100.57%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Beam Therapeutics has a net margin of -54.75% compared to Intellia Therapeutics' net margin of -672.16%. Beam Therapeutics' return on equity of -30.71% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Intellia Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, meaning that its share price is 120% more volatile than the broader market.

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Beam Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Beam Therapeutics has a net margin of -54.75% compared to Prime Medicine's net margin of -4,613.11%. Beam Therapeutics' return on equity of -30.71% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	115.76	-$201.14M	-$1.06	N/A
Beam Therapeutics	$139.74M	18.06	-$79.99M	-$0.86	N/A

Prime Medicine has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, meaning that its stock price is 120% more volatile than the broader market.

In the previous week, Beam Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Beam Therapeutics and 6 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.44 beat Beam Therapeutics' score of 0.23 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine presently has a consensus target price of $7.47, suggesting a potential upside of 152.87%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 100.57%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Beam Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

Get Beam Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAM vs. The Competition

Export

Metric	Beam Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.53B	$3.84B	$7.11B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-28.46	13.44	274.42	26.03
Price / Sales	18.09	1,285.38	600.72	89.51
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	2.01	16.64	10.92	6.32
Net Income	-$79.99M	-$22.67M	$3.50B	$361.43M
7 Day Performance	0.83%	-2.99%	-2.07%	-1.66%
1 Month Performance	-16.45%	-10.68%	-6.32%	-3.93%
1 Year Performance	-4.37%	21.44%	8.92%	2.82%

Beam Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAM Beam Therapeutics	2.5915 of 5 stars	$24.47 +0.3%	$49.00 +100.2%	+1.1%	$2.53B	$139.74M	N/A	540	Gap Up
CRSP CRISPR Therapeutics	2.8097 of 5 stars	$54.09 -0.3%	$67.94 +25.6%	-16.2%	$5.24B	$3.51M	N/A	393
DNLI Denali Therapeutics	2.6824 of 5 stars	$20.98 +2.9%	$35.85 +70.9%	+37.7%	$3.26B	$330.53M	N/A	507
EDIT Editas Medicine	1.7592 of 5 stars	$2.51 -2.7%	$5.80 +131.1%	-29.0%	$396.24M	$40.52M	N/A	87
NTLA Intellia Therapeutics	3.0943 of 5 stars	$11.42 -2.8%	$20.98 +83.7%	-35.4%	$1.65B	$67.67M	N/A	377	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAM) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beam Therapeutics (BEAM) Competitors

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

How does Beam Therapeutics compare to CRISPR Therapeutics?

Do insiders and institutionals hold more shares of CRSP or BEAM?

Which has stronger earnings and valuation, CRSP or BEAM?

Does the media prefer CRSP or BEAM?

Which has more risk & volatility, CRSP or BEAM?

Is CRSP or BEAM more profitable?

Do analysts recommend CRSP or BEAM?

Summary

How does Beam Therapeutics compare to Denali Therapeutics?

Which has stronger valuation & earnings, DNLI or BEAM?

Does the media refer more to DNLI or BEAM?

Do analysts recommend DNLI or BEAM?

Is DNLI or BEAM more profitable?

Which has more risk and volatility, DNLI or BEAM?

Do institutionals & insiders hold more shares of DNLI or BEAM?

Summary

How does Beam Therapeutics compare to Editas Medicine?

Which has more risk and volatility, BEAM or EDIT?

Does the media prefer BEAM or EDIT?

Do institutionals & insiders believe in BEAM or EDIT?

Is BEAM or EDIT more profitable?

Do analysts recommend BEAM or EDIT?

Which has higher earnings and valuation, BEAM or EDIT?

Summary

How does Beam Therapeutics compare to Intellia Therapeutics?

Which has preferable earnings and valuation, NTLA or BEAM?

Does the media refer more to NTLA or BEAM?

Do analysts rate NTLA or BEAM?

Do institutionals & insiders believe in NTLA or BEAM?

Is NTLA or BEAM more profitable?

Which has more volatility & risk, NTLA or BEAM?

Summary

How does Beam Therapeutics compare to Prime Medicine?

Is PRME or BEAM more profitable?

Do institutionals & insiders believe in PRME or BEAM?

Which has better valuation & earnings, PRME or BEAM?

Which has more volatility and risk, PRME or BEAM?

Does the media favor PRME or BEAM?

Do analysts rate PRME or BEAM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM vs. The Competition

Beam Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools